These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21265873)

  • 1. α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.
    Yamada S; Ito Y; Tsukada H
    Br J Clin Pharmacol; 2011 Aug; 72(2):205-17. PubMed ID: 21265873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder.
    Yoshida A; Fujino T; Maruyama S; Ito Y; Taki Y; Yamada S
    J Pharmacol Sci; 2010; 112(2):142-50. PubMed ID: 20134113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment.
    Maruyama S; Tsukada H; Nishiyama S; Kakiuchi T; Fukumoto D; Oku N; Yamada S
    J Pharmacol Exp Ther; 2008 Jun; 325(3):774-81. PubMed ID: 18326811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic receptors in the bladder: from basic research to therapeutics.
    Hegde SS
    Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum.
    Wuest M; Witte LP; Michel-Reher MB; Propping S; Braeter M; Strugala GJ; Wirth MP; Michel MC; Ravens U
    World J Urol; 2011 Apr; 29(2):149-55. PubMed ID: 21336600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
    Maruyama S; Hasuike N; Suzuki K; Yamada S
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):463-71. PubMed ID: 18074121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
    J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
    Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
    Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
    Mansfield KJ; Chandran JJ; Vaux KJ; Millard RJ; Christopoulos A; Mitchelson FJ; Burcher E
    J Pharmacol Exp Ther; 2009 Mar; 328(3):893-9. PubMed ID: 19029429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia.
    Yamada S; Kato Y; Okura T; Kagawa Y; Kawabe K
    Biol Pharm Bull; 2007 Jul; 30(7):1237-41. PubMed ID: 17603160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
    Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
    Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
    Yamaguchi O
    Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study on pharmacokinetics and in vivo alpha1-adrenoceptor binding of [3H]tamsulosin and [3H]prazosin in rats.
    Ohkura T; Yamada S; Deguchi Y; Kimura R
    Biol Pharm Bull; 1999 Apr; 22(4):412-7. PubMed ID: 10328564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder.
    Shiho M; Akashita G; Nakatani E; Tanaka S; Yamada S; Okura T
    Drug Metab Pharmacokinet; 2024 Jun; 56():100998. PubMed ID: 38583388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213)].
    Tatemichi S; Kobayashi K; Maezawa A; Kobayashi M; Yamazaki Y; Shibata N
    Yakugaku Zasshi; 2006 Mar; 126 Spec no.():209-16. PubMed ID: 16518085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.
    Sinha S; Gupta S; Malhotra S; Krishna NS; Meru AV; Babu V; Bansal V; Garg M; Kumar N; Chugh A; Ray A
    Br J Pharmacol; 2010 Jul; 160(5):1119-27. PubMed ID: 20590605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.
    Kenny BA; Miller AM; Williamson IJ; O'Connell J; Chalmers DH; Naylor AM
    Br J Pharmacol; 1996 Jun; 118(4):871-8. PubMed ID: 8799556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.
    Taguchi K; Schäfers RF; Michel MC
    Br J Clin Pharmacol; 1998 Jan; 45(1):49-55. PubMed ID: 9489594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.